If the previous management of Air Products had delivered a quarter that included the following, the stock would have been down meaningfully on the day: A year on year decline in operating income from its core gases business A write
TMT: Portfolio Update – Dreams, Comebacks, Skeptics and the Death Watch Redux Last quarter, we created a framework to assess TMT stocks, juxtaposing near-term cash flow expectations (5-year consensus cash flows) with long term expectations (post 5 year cash
We have touched on the subject of inventory drawdown in Q4 in a couple of recent reports, but the more we think about the subject and refer back to history, the more we believe that this could be the most
Drug, biotech, and research-based spec pharma stocks tend to outperform their peers in the year or so before and after regulatory actions (‘PDUFA’ dates) on major new products, with a large portion of total risks being concentrated in the days